OmniAb Inc.
$ 2.34
-1.68%
11 Jun - close price
- Market Cap 345,035,000 USD
- Current Price $ 2.34
- High / Low $ 2.47 / 2.30
- Stock P/E N/A
- Book Value 1.81
- EPS -0.46
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.11 %
- ROE -0.20 %
- 52 Week High 2.79
- 52 Week Low 1.30
About
OmniAb Inc. is an innovative biotechnology company specializing in the development of fully human therapeutic antibodies via its proprietary OmniAb platform. This advanced technology enables the swift discovery and refinement of highly effective therapies aimed at addressing a wide spectrum of diseases. By leveraging strategic partnerships and collaborations, OmniAb aims to accelerate drug development processes and enhance access to groundbreaking treatments. With a seasoned leadership team and a robust pipeline of candidates, the company is strategically positioned to capitalize on the growing opportunities within the biopharmaceutical industry.
Analyst Target Price
$7.33
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-03-04 | 2025-11-04 | 2025-08-06 | 2025-05-08 | 2025-03-18 | 2024-11-12 | 2024-08-08 | 2024-05-09 | 2024-03-20 | 2023-11-09 | 2023-08-10 |
| Reported EPS | -0.06 | -0.11 | -0.14 | -0.15 | -0.17 | -0.12 | -0.16 | -0.13 | -0.19 | -0.14 | -0.16 | -0.15 |
| Estimated EPS | -0.0967 | -0.0875 | -0.13 | -0.13 | -0.1667 | -0.0967 | -0.14 | -0.17 | -0.16 | -0.15 | -0.14 | -0.12 |
| Surprise | 0.0367 | -0.0225 | -0.01 | -0.02 | -0.0033 | -0.0233 | -0.02 | 0.04 | -0.03 | 0.01 | -0.02 | -0.03 |
| Surprise Percentage | 37.9524% | -25.7143% | -7.6923% | -15.3846% | -1.9796% | -24.0951% | -14.2857% | 23.5294% | -18.75% | 6.6667% | -14.2857% | -25% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: OABI
2026-05-23 14:08:54
This article lists several health care stocks that experienced significant movement during Wednesday's pre-market session. It details both gainers, such as Silexion Therapeutics and Jupiter Neurosciences, and losers, including Annovis Bio and Virax Biolabs Group, along with their respective stock changes, market caps, and recent earnings report dates.
2026-05-16 07:17:11
This article provides an analysis of OmniAb, Inc. (OABI) stock, including its current price, fundamental financials, and corporate information. It details how to buy OABI stock on the Gotrade app, explains that OABI does not currently pay dividends, and offers guidance on evaluating if the stock is expensive or cheap. OmniAb Inc. licenses discovery research technology for next-generation therapeutics, utilizing its OmniAb platform and "Biological Intelligence" to create optimized antibody candidates.
2026-05-11 23:39:16
OmniAb, Inc. (NASDAQ:OABI) released its Q1 2026 earnings, reporting an EPS of -$0.06, which beat estimates by $0.04. The company's revenue reached $14.43 million, significantly surpassing expectations by $8.83 million and representing a substantial 247.30% year-over-year increase. This article presents the slide deck from their Q1 earnings call.
2026-05-11 12:08:47
This article analyzes OmniAb's (NASDAQ:OABI) cash position and burn rate, highlighting the importance of wise cash utilization for growth companies that are not yet profitable. The company currently holds $165.7 million in cash and short-term investments, with a burn rate suggesting it could fund operations for approximately 2.9 years. The article emphasizes that while OmniAb's cash runway appears adequate, investor confidence will depend on how effectively this capital is deployed to achieve future profitability.
2026-05-11 03:09:43
This article provides financial information for OmniAb, Inc. (NASDAQ: OABIW), focusing on its number of shareholders. It appears to be a stub or data-focused page from TradingView, presenting a barebones overview with copyright and product information. The core content is the heading "Number of shareholders of OmniAb, Inc." followed by "Period Value Change Change %," suggesting that the actual data points would be displayed below this structure.
2026-05-10 06:09:43
OmniAb (OABI) reported a FY 2025 net loss of US$64.8 million, with a fourth-quarter revenue of US$8.4 million and a basic EPS loss of US$0.11. The company's profitability is under scrutiny, with sustained losses and forecasts predicting unprofitability for at least the next three years, leading to concerns about potential shareholder dilution, despite a forecasted 30.8% annual revenue growth and a strong partner ecosystem. The stock trades at a high P/S ratio of 11.4x, significantly above its DCF fair value of US$5.21 and analyst target of US$7.33, creating a valuation tension between growth potential and ongoing losses.
